Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Clinical Investigation on Feasibility and Usability of the ABLE Exoskeleton Device for Individuals With Spinal Cord Injury to Perform Skills for Home and Community Environments

NCT05643313 · ABLE Human Motion S.L. · Updated 19 Oct 2023

What is being tested
ABLE Exoskeleton
For
Spinal Cord Injuries
Kind of study
Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
Who can join
Ages 18 years to 70 years. About 10 people. The full rules are on the registry page.
Where
Germany, Spain (2 sites)
When
Starts or started 25 Nov 2022, ends 28 Aug 2023. Registered 8 Dec 2022.
Results
None posted yet.

In the researchers' words

The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians. Exoskeletal technology has the potential to help people with impaired leg function to regain ambulation and thus improve their independence. This technology is not completely new, but due to their high access price (\~120k€/unit), high size and weight (\~25 kg), and need for trained physiotherapist supervision, commercially available exoskeletons are only found in large hospitals and only in very few cases get into patients' homes. The company ABLE Human Motion S.L. (Barcelona, Spain) has developed a novel exoskeleton to overcome these disadvantages, which is more compact, lighter and easier to use. The primary objective of this study is to determine the feasibility and usability of the ABLE Exoskeleton for persons with SCI to perform skills in home and community environments.
ClinicalTrials.gov, NCT05643313

Sites

  • Spinal Cord Injury Center | Heidelberg University HospitalHeidelberg, Germany
  • Institut GuttmannBadalona, Barcelona, Spain